Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176800 | 0.91 | PRMT5 (0.47) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL4167265 | 0.91 | PRMT5 (0.47) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL21518491 | 0.91 | PRMT5 (0.47) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL21458541 | 0.88 | HPGD (0.46) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL3658834 | 0.88 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL26352427 | 0.88 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL21458526 | 0.87 | HPGD (0.45) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL21458497 | 0.87 | HPGD (0.45) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL21458885 | 0.87 | HPGD (0.45) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL4107865 | 0.86 | HPGD (0.49) | HPGDGPR119RECQLEPHX1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024263860-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240180954-A1 | CATIONIC LIPID | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| WO-2024077244-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077244-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-117836299-A | Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof | 韩国化学研究院 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024067304-A1 | COMPOUND WITH INHIBITORY ACTIVITY AGAINST SIGMA2 AND 5HT2A AND USE | 瀚远医药有限公司 | 2024-04-04 | — | — | WO | disclosed |
| US-5789595-A | ANTICOAGULANTS | TERUMO KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5760057-A | ANTICOAGULANTS | ZENECA LIMITED (GB) | 1998-06-02 | — | — | US | disclosed |
| US-5726185-A | BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELET AGGREGATION AND CELL TO CELL ADHESION | HOFFMANN-LA ROCHE INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0790247-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND MEDICINAL PREPARATION CONTAINING THE SAME | TERUMO KABUSHIKI KAISHA (JP) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
| EP-0632016-B1 | 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors | ZENECA LTD (GB) | 1997-04-09 | — | — | EP | disclosed |
| US-5612373-A | ANTICOAGULANTS | ZENECA LIMITED (GB) | 1997-03-18 | — | — | US | disclosed |
| EP-0656348-A2 | Aceric acid derivatives as medicaments | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995000472-A1 | 1,2 DIACYLATED HYDRAZINE DERIVATIVES AND THEIR USE AS ALL ADHESION INHIBITORS | ZENECA LIMITED (GB) | 1995-01-05 | — | — | WO | disclosed |
| EP-0632016-A1 | 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors | ZENECA LIMITED (GB) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | HPGD 193/4885GPR119 1990/4885RECQL 216/4885 |
| US-20240180954-A1 | CATIONIC LIPID | APOB, NPC1L1, SGMS1 | HPGD 4689/4885GPR119 606/4885RECQL 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.